Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Thrombin Receptor Antagonism in Antiplatelet Therapy

Thrombin Receptor Antagonism in Antiplatelet Therapy Activated platelets play a crucial role in the pathogenesis of atherothrombotic disease and its complications. Even under treatment of antiplatelet drugs, such as acetylsalicylic acid and P2Y12 antagonists, morbidity and mortality rates of thromboembolic complications remain high. Hence, the therapeutic inhibition of protease-activated receptor (PAR)-1, which is activated by thrombin, is a novel promising approach in antiplatelet therapy. Recent data suggest that PAR-1 is mainly involved in pathological thrombus formation, but not in physiological hemostasis. Therefore, PAR-1 inhibition offers the possibility to reduce atherothrombotic events without increasing bleeding risk. So far, two emerging PAR-1 antagonists have been tested in clinical trials: vorapaxar (SCH530349; Merck & Co., Whitehouse Station, NJ, USA) and atopaxar (E5555; Eisai, Tokyo, Japan). Although in TRA-CER vorapaxar showed an unfavorable profile for patients with acute coronary syndrome in addition to standard therapy, it revealed promising results for patients with prior myocardial infarction in TRA 2P-TIMI50. Depending on the status of clinical approval, vorapaxar might be an option for patients with peripheral arterial disease to reduce limb ischemia. The second PAR-I antagonist, atopaxar, tended towards reducing major cardiovascular adverse events in acute coronary syndrome patients in a phase II trial. However, although statistically not significant, bleeding events were numerically increased in atopaxar-treated patients compared with placebo. Furthermore, liver enzymes were elevated and the relative corrected QT interval was prolonged in atopaxar-treated patients. Currently, the development of atopaxar by Eisai is discontinued. The future of this novel class of antithrombotic drugs will depend on the identification of patient groups in which the risk–benefit ratio is favorable. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiology and Therapy Springer Journals

Thrombin Receptor Antagonism in Antiplatelet Therapy

Olivier, C.; Diehl, P.; Bode, C.; Moser, M.
Cardiology and Therapy , Volume 2 (1) – Mar 7, 2013
Download PDF
12 pages

Loading next page...
 
/lp/springer-journals/thrombin-receptor-antagonism-in-antiplatelet-therapy-NHHYk1tkRc
Publisher
Springer Journals
Copyright
Copyright © 2013 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Cardiology
ISSN
2193-8261
eISSN
2193-6544
DOI
10.1007/s40119-013-0013-4
pmid
25135289
Publisher site
See Article on Publisher Site

Abstract

Activated platelets play a crucial role in the pathogenesis of atherothrombotic disease and its complications. Even under treatment of antiplatelet drugs, such as acetylsalicylic acid and P2Y12 antagonists, morbidity and mortality rates of thromboembolic complications remain high. Hence, the therapeutic inhibition of protease-activated receptor (PAR)-1, which is activated by thrombin, is a novel promising approach in antiplatelet therapy. Recent data suggest that PAR-1 is mainly involved in pathological thrombus formation, but not in physiological hemostasis. Therefore, PAR-1 inhibition offers the possibility to reduce atherothrombotic events without increasing bleeding risk. So far, two emerging PAR-1 antagonists have been tested in clinical trials: vorapaxar (SCH530349; Merck & Co., Whitehouse Station, NJ, USA) and atopaxar (E5555; Eisai, Tokyo, Japan). Although in TRA-CER vorapaxar showed an unfavorable profile for patients with acute coronary syndrome in addition to standard therapy, it revealed promising results for patients with prior myocardial infarction in TRA 2P-TIMI50. Depending on the status of clinical approval, vorapaxar might be an option for patients with peripheral arterial disease to reduce limb ischemia. The second PAR-I antagonist, atopaxar, tended towards reducing major cardiovascular adverse events in acute coronary syndrome patients in a phase II trial. However, although statistically not significant, bleeding events were numerically increased in atopaxar-treated patients compared with placebo. Furthermore, liver enzymes were elevated and the relative corrected QT interval was prolonged in atopaxar-treated patients. Currently, the development of atopaxar by Eisai is discontinued. The future of this novel class of antithrombotic drugs will depend on the identification of patient groups in which the risk–benefit ratio is favorable.

Journal

Cardiology and Therapy – Springer Journals

Published: Mar 7, 2013

References

  • Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data
    Lopez, AD; Mathers, CD; Ezzati, M; Jamison, DT; Murray, CJ
  • Platelet activation and atherothrombosis
    Davi, G; Patrono, C
  • Mechanisms of thrombus formation
    Furie, B; Furie, BC
  • 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
    Jneid, H; Anderson, JL; Wright, RS
  • ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)
    Steg, PG; James, SK; Atar, D
  • ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
    Werf, F; Bax, J; Betriu, A
  • Impact of clopidogrel and potent P2Y12-inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention. Systematic review and meta-analysis
    Aradi, D; Komócsi, A; Vorobcsuk, A; Serebruany, VL
  • Platelet thrombin receptor antagonism and atherothrombosis
    Angiolillo, DJ; Capodanno, D; Goto, S
  • Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study)
    Fox, KA; Carruthers, KF; Dunbar, DR
  • Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives
    Angiolillo, DJ; Fernandez-Ortiz, A; Bernardo, E
  • Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis
    Combescure, C; Fontana, P; Mallouk, N
  • Prasugrel versus clopidogrel in patients with acute coronary syndromes
    Wiviott, SD; Braunwald, E; McCabe, CH
  • Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    Wallentin, L; Becker, RC; Budaj, A
  • Proteinase-activated receptors
    Macfarlane, SR; Seatter, MJ; Kanke, T; Hunter, GD; Plevin, R
  • Thrombin receptor-mediated vascular relaxation differentiated by a receptor antagonist and desensitization
    Tesfamariam, B
  • Thrombin causes endothelium-dependent biphasic regulation of vascular tone in the porcine renal interlobar artery
    Derkach, DN; Ihara, E; Hirano, K; Nishimura, J; Takahashi, S; Kanaide, H
  • Receptor mechanism of thrombin-induced endothelium-dependent and endothelium-independent coronary vascular effects in dogs
    Ku, DD; Zaleski, JK
  • Protease-activated receptors in hemostasis, thrombosis and vascular biology
    Coughlin, SR
  • Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity
    Andersen, H; Greenberg, DL; Fujikawa, K; Xu, W; Chung, DW; Davie, EW
  • An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey
    Cook, JJ; Sitko, GR; Bednar, B
  • Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates
    Derian, CK; Damiano, BP; Addo, MF
  • Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig
    Kato, Y; Kita, Y; Hirasawa-Taniyama, Y
  • Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis
    Vandendries, ER; Hamilton, JR; Coughlin, SR; Furie, B; Furie, BC
  • Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events
    Tomasello, SD; Angiolillo, DJ; Goto, S
  • The novel and orally active thrombin receptor antagonist E5555 (atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs
    Kogushi, M; Matsuoka, T; Kawata, T
  • Oral administration of the thrombin receptor antagonist E5555 (atopaxar) attenuates intimal thickening following balloon injury in rats
    Kogushi, M; Matsuoka, T; Kuramochi, H
  • The in vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease
    Serebruany, VL; Kogushi, M; Dastros-Pitei, D; Flather, M; Bhatt, D
  • Pharmacodynamics and safety of a novel protease activated receptor-1 antagonist E5555 for healthy volunteers
    Takeuchi, M
  • Double-blind, placebo-controlled phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease
    Goto, S; Ogawa, H; Takeuchi, M
  • Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes Trial
    O’Donoghue, ML; Bhatt, DL; Wiviott, SD
  • Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease Trial
    Wiviott, SD; Flather, MD; O’Donoghue, ML
  • The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease
    Mehta, SR; Yusuf, S
  • Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial
    Bovill, EG; Terrin, ML; Stump, DC
  • SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys
    Chintala, M; Vemulapalli, S; Kurowski, S
  • Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity
    Chackalamannil, S; Wang, Y; Greenlee, WJ
  • Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
    Becker, RC; Moliterno, DJ; Jennings, LK
  • Thrombin-receptor antagonist vorapaxar in acute coronary syndromes
    Tricoci, P; Huang, Z; Held, C
  • Vorapaxar in the secondary prevention of atherothrombotic events
    Morrow, DA; Braunwald, E; Bonaca, MP
  • Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge
    Chesebro, JH; Knatterud, G; Roberts, R
  • Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial
    Morrow, DA; Scirica, BM; Fox, KA
  • Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial
    Scirica, BM; Bonaca, MP; Braunwald, E
  • Vorapaxar for secondary prevention in patients with peripheral artery disease: results from the peripheral artery disease cohort of the TRA2°P-TIMI 50 Trial
    Bonaca, MP; Morrow, DA; Braunwald, E
  • Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism?
    Duerschmied, D; Bode, C
  • Matrix metalloproteases and PAR1 activation
    Austin, KM; Covic, L; Kuliopulos, A
  • Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin
    Zhang, P; Gruber, A; Kasuda, S
  • PAR-1 antagonists: current state of evidence
    Chatterjee, S; Sharma, A; Mukherjee, D